Yohimbine Enhancement of Exposure Therapy for Social Anxiety Disorder: A Randomized Controlled Trial

Department of Psychology and Institute for Mental Health Research (JAJS, MLD, MBP), The University of Texas at Austin, Austin. Electronic address: .
Biological psychiatry (Impact Factor: 10.26). 10/2013; 75(11). DOI: 10.1016/j.biopsych.2013.10.008
Source: PubMed


Preclinical and clinical trials suggest that yohimbine may augment extinction learning without significant side effects. However, previous clinical trials have only examined adults with specific phobias. Yohimbine has not yet been investigated in the augmentation of exposure therapy for other anxiety disorders.
Adults (n = 40) with a DSM-IV diagnosis of social anxiety disorder were randomized to placebo or yohimbine HCl (10.8 mg) 1 hour before each of four exposure sessions. Outcome measures were collected at baseline, each treatment session, posttreatment, and 1-month follow-up.
Yohimbine was well tolerated. Yohimbine augmentation, relative to placebo augmentation, resulted in faster improvement and better outcomes on self-report measures of social anxiety disorder severity (Liebowitz Social Anxiety Scale, d = .53) and depressed mood severity (Beck Depression Inventory, d = .37) but not on the clinician-rated measures (Clinical Global Impressions-Severity Scale, d = .09; Clinical Global Impressions-Improvement Scale, d = .25). Between-group differences on the Liebowitz Social Anxiety Scale were moderated by the level of fear reported at the end of an exposure exercise (end fear), such that the advantage of yohimbine over placebo was only evident among patients who reported low end fear.
The results provide moderate support for yohimbine as a therapeutic augmentation strategy for exposure therapy in social anxiety disorder, one that may be especially effective when coupled with successful exposure experiences. Beneficial effects for yohimbine were readily evident for self-report measures but not for clinician-rated outcomes of social anxiety severity and improvement.


Available from: Stefan G Hofmann, Oct 14, 2014
  • Source
    • "Our findings are incongruent with the putative mechanism of action of DCS augmentation (i.e., enhancement of extinction learning consolidation), and evidence from preclinical and prior clinical research that demonstrated that the degree of extinction learning during extinction training/exposure therapy moderated the efficacy of DCS enhancement for several anxiety disorders (Bolkan & Lattal, 2014; Bouton et al., 2008; Smits, Rosenfield, Otto, Marques, et al., 2013a; Smits, Rosenfield, Otto, Powers, et al., 2013b; Weber et al., 2007), including PTSD (Rothbaum et al., 2014). Interestingly, two additional studies have since documented that the efficacy of other cognitive enhancers of exposure therapy (e.g., yohimbine, methylene blue) also depends on the level of extinction learning as indexed by low end fear (Smits et al., 2014; Telch et al., 2014). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Augmentation of exposure therapy with d-cycloserine (DCS) has proven efficacious across anxiety disorders, although results in PTSD have been mixed. Work in animals and anxiety-disordered patients suggest that the potentiating effects of DCS are dependent on the level of extinction learning during extinction training and exposure treatment, respectively. The aim of the current study was to replicate and extend previous work by examining the association between the degree of extinction learning and DCS efficacy in our randomized clinical trial on DCS (50mg) versus placebo enhancement of exposure therapy in a chronic mixed-trauma PTSD sample (N=67; de Kleine, Hendriks, Kusters, Broekman, & van Minnen, 2012). The decline in subjective units of distress ratings collected during and across the exposure sessions were evaluated as indices of extinction learning. First, we examined whether extinction learning during an exposure session moderated DCS effects on self-reported PTSD symptoms at the next session. Second, we examined whether averaged extinction learning over the course of treatment interacted with group assignment to predict change over time and post treatment outcome. We did not find evidence that DCS effects were moderated by the degree of extinction learning, although, extinction learning was related to outcome regardless of group assignment. In PTSD, not one extinction-learning index has been consistently linked to DCS enhanced exposure treatment outcome. More (experimental) work needs to been done to unravel the complex interplay between extinction learning and DCS enhancement, especially in PTSD patients. Copyright © 2015 Elsevier Ltd. All rights reserved.
    Journal of anxiety disorders 06/2015; 34. DOI:10.1016/j.janxdis.2015.06.005 · 2.68 Impact Factor
  • Source
    • "A number of so-called cognitive enhancers have been uncovered, including yohimbine that increases central noradrenergic transmission (Tam et al. 2001). Following an initial report of several years ago where yohimbine facilitated extinction in mice (Cain, Blouin, & Barad, 2004), recent studies have shown moderate to mixed effects of yohimbine as adjunct to extinction learning (Holmes & Quirk, 2010; Smits et al., 2014). An important limitation of this novel strategy is that it does not eradicate the original fear memory: The conditioned fear response returned when the animals were tested outside of the extinction context (Morris & Bouton, 2007). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Over the past decades, behaviour and cognitive psychology have produced fruitful and mutually converging theories from which hypotheses could be derived on the nature and origin of fear and anxiety disorders. Notwithstanding the emergence of effective treatments, there are still many questions that remain to be answered. Here, I will argue that the burgeoning field of behavioural neuroscience may advance our understanding of fear, anxiety disorders and its treatments. Decades of fear-conditioning research across species have begun to elucidate the neurobiological mechanisms underlying associative fear learning and memory. The fear-conditioning paradigm provides a well-controlled and fine-grained research platform to examine these processes. Although the traditional fear conditioning paradigm was originally designed to unveil general principles of fear (un)learning, it is well-suited to understand the transition from normal fear to pathological fear and the mechanisms of change. This paper presents 1) a selection of fear conditioning studies on the generalization and persistence of associative fear memory as intermediate phenotypes of fear and anxiety disorders, and 2) insights from neuroscience on the malleability of fear memory with the potential to provide a long-term cure for anxiety and related disorders.
    Behaviour Research and Therapy 09/2014; 62. DOI:10.1016/j.brat.2014.08.012 · 3.85 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Translating findings from basic science, several compounds have been identified that may enhance therapeutic outcomes and/or expedite treatment gains when administered alongside exposure-based treatments. Four of these compounds (referred to as cognitive enhancers) have been evaluated in the context of randomized controlled trials for anxiety disorders (e.g., specific phobias, panic disorder, social anxiety disorder), obsessive-compulsive disorder and post-traumatic stress disorder. These cognitive enhancers include d-cycloserine, yohimbine hydrochloride, glucocorticoids and cortisol and brain-derived neurotrophic factor. There is consistent evidence that cognitive enhancers can enhance therapeutic outcomes and/or expedite treatment gains across anxiety disorders, obsessive-compulsive disorder and post-traumatic stress disorder. Emerging evidence has highlighted the importance of within-session fear habituation and between-session fear learning, which can either enhance fear extinction or reconsolidate of fear responses. Although findings from these trials are promising, there are several considerations that warrant further evaluation prior to widespread use of cognitive enhancers in exposure-based treatments. Consistent trial design and large sample sizes are important in future studies of cognitive enhancers.
    Expert Review of Neurotherapeutics 06/2014; 14(8):1-18. DOI:10.1586/14737175.2014.934677 · 2.78 Impact Factor
Show more